Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
Prof. Thomas Helmut Schindler
View the Slides from this session in ESC Congress 365
A variety of cardiovascular imaging modalities are increasingly applied for research and clinical investigations. With the advent of the introduction of PET/CT and PET/MRI, cardiovascular imaging may allow a comprehensive identification and characterization of cardiovascular pathology and, moving forward to molecular imaging, may identify potential new targets in the prevention and/or treatment of cardiovascular disease.
Prof. Paul Knaapen (Amsterdam, NL) illustrated the increased use of non-invasively and PET-determined myocardial flow reserve (MFR) in the clinical field for the identification and characterization of CAD burden in multivessel disease. He outlined flow thresholds that may signify flow-limiting effects of each stenosed coronary vessel in multivessel disease, which may enable the interventional cardiologist and/or cardiovascular surgeon a more differentiated and individualized treatment approach for coronary revascularization. The added prognostic value of an abnormal MFR was also discussed, which may reflect a target for preventive measures in CAD patients.
Prof. Markus Schwaiger (Munich, DE) summarized the outstanding potential of cardiac PET/MRI in signifying and characterizing tissue injury of the myocardium after myocardial infarction or in cardiomyopathy. Combining anatomic, functional, metabolic, and molecular imaging information with PET/MRI affords a comprehensive assessment of hibernating-stunning myocardium, the inflammatory, immunologic, and reparative mechanism in acute and chronic myocardial infarction model with associated remodelling of the left ventricle. Notably, PET/MRI may be most suitable in the identification of novel targets for the prevention and treatment of heart failure patients.
Prof. Eike Nagel (London, GB) provided an excellent and comprehensive overview of the use of cardiac MRI in concert with T1-mapping for the assessment of the extracellular myocardial space as surrogate marker of interstitial myocardial fibrosis, which carries important diagnostic and prognostic information and may be used in the clinical setting in the near future. This novel diagnostic approach may also aid in a better understanding of underlying pathology in heart failure patients with different origins.
Prof. Paolo Camici (Milano, IT) excellently summarized previous and recent development in receptor imaging of the heart with focus on cardiomyopathy and risk stratification. The use of various radiotracers such as I123-MIBG, 11C-HED, and 11C-CGP in cardiomyopathy patients and their clinical and prognostic value were discussed. Applying nuclear receptor imaging techniques with SPECT or PET are most helpful, for example, in signifying impaired sympathetic innervations and expression of B-blockers in the failing myocardium, which may aid the cardiologist in the decision-making process for various treatment options of heart failure patients and monitoring therapy.
Advances in the identification and characterisation of coronary artery disease and cardiomyopathy
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved